- 上一篇：金融扶持文化产业文献综述和参考文献
- 下一篇：空巢老人文献综述和参考文献
(10) Boström, J.; Grant, A. Molecular drug properties: measurementand prediction. In Exploiting Ligand Conformations in Drug Design;Wiley−VCH: Weinheim, Germany, 2007; Vol. 37, pp 183−205.
(11) Hao, M. H.; Haq, O.; Muegge, I. Torsion angle preference andenergetics of small-molecule ligands bound to proteins. J. Chem. Inf.Model. 2007, 47, 2242−52.
(12) Perola, E.; Charifson, P. S. Conformational analysis of drug-likemolecules bound to proteins: an extensive study of ligand reorganizationupon binding. J. Med. Chem. 2004, 47, 2499−2510.
(13) Sitzmann, M.; Weidlich, I. E.; Filippov, I. V.; Liao, C.; Peach, M.L.; Ihlenfeldt, W.-D.; Karki, R. G.; Borodina, Y. V.; Cachau, R. E.;Nicklaus, M. C. PDB ligand conformational energies calculatedquantum-mechanically. J. Chem. Inf. Model. 2012, 52, 739−756.
(14) Tirado-Rives, J.; Jorgensen, W. L. Contribution of conformerfocusing to the uncertainty in predicting free energies for protein−ligandbinding. J. Med. Chem. 2006, 49, 5880−5884.
(15) D’Amico, D. C.; Aya, T.; Shuman, J.; Fotsch, C.; Chen, J. J.;Biswas, K.; Riahi, B.; Norman, M. H.; Willoughby, C. A.; Hungate, R.;Reider, P. J.; Biddlecome, G.; Lester-Zeiner, D.; Staden, C. V.; Johnson,E.; Kamassah, A.; Arik, L.; Wang, J.; Viswanadhan, V. N.;Groneberg, R.D.; Zhan, J.; Suzuki, H.; Toro, A.; Mareska, D. A.; Clarke, D. E.; Harvey,D. M.; Burgess, L. E.; Laird, E. R.; Askew, B.; Ng, G. Identification of anonpeptidic and conformationally restricted bradykinin B1 receptorantagonist with anti-inflammatory activity. J. Med. Chem. 2007, 50, 607−610.
(16) Ikegashira, K.; Oka, T.; Hirashima, S.; Noji, S.; Yamanaka, H.;Hara, Y.; Adachi, T.; Tsuruha, J.-I.; Doi, S.; Hase, Y.; Noguchi, T.; Ando,I.; Ogura, N.; Ikeda, S.; Hashimoto, H. Discovery of conformationallyconstrained tetracyclic compounds as potent hepatitis C virus NS5BRNA polymerase inhibitors. J. Med. Chem. 2006, 49, 6950−6953.
(17) Martin, S. F. Preorganization in biological systems: Areconformational constraints worth the energy? Pure Appl. Chem. 2007,79, 193−200.(18) Gaali, S.; Gopalakrishnan, R.; Wang, Y.; Kozany, C.; Hausch, F.The chemical biology of immunophilin ligands. Curr. Med. Chem. 2011,18, 5355−5379.
(19) Schmidt, M. V.; Paez-Pereda, M.; Holsboer, F.; Hausch, F. Theprospect of FKBP51 as a drug target. ChemMedChem 2012, 8, 1351−1359.
(20) Fabian, A.-K.; März, A.; Neimanis, S.; Biondi, R. M.; Kozany, C.;Hausch, F. InterAKTions with FKBPs: Mutational and pharmacologicalexploration. PLoS One 2013, 8, e57508.
(21) März, A. M.; Fabian, A.-K.; Kozany, C.; Bracher, A.; Hausch, F.Large FK506-binding proteins shape the pharmacology of rapamycin.Mol. Cell. Biol. 2013, 33, 1357−1367.
(22) Gopalakrishnan, R.; Kozany, C.; Gaali, S.; Kress, C.; Hoogeland,B.; Bracher, A.; Hausch, F. Evaluation of synthetic FK506 analogues asligands for the FK506-binding proteins 51 and 52. J. Med. Chem. 2012,55, 4114−4122.(23) Gopalakrishnan, R.; Kozany, C.; Wang, Y.; Schneider, S.;Hoogeland, B.; Bracher, A.; Hausch, F. Exploration of pipecolatesulfonamides as binders of the FK506-binding proteins 51 and 52. J.Med. Chem. 2012, 55, 4123−4131.
(24) Holt, D. A.; Luengo, J. I.; Yamashita, D. S.; Oh, H. J.; Konilian, A.L.; Yen, H. K.; Rozamus, L. W.; Brandt, M.; Bossard, M. J.; Levy, M. A.;Eggleston, D. S.; Liang, J.; Schultz, W.; Stout, T. J.; Clardy, J. Design,synthesis, and kinetic evaluation of high-affinity FKBP ligands and the Xraycrystal structures of their complexes with FKBP 12. J. Am. Chem. Soc.
1993, 115, 9925−9938.
(25) Hudack, R. A., Jr.; Barta, N. S.; Guo, C.; Deal, J.; Dong, L.; Fay, L.K.; Caprathe, B.; Chatterjee, A.; Vanderpool, D.; Bigge, C.; Showalter,R.; Bender, S.; Augelli-Szafran, C. E.; Lunney, E.; Hou, X. Design,synthesis, and biological activity of novel polycyclic aza-amide FKBP12ligands. J. Med. Chem. 2006, 49, 1202−1206.
(26) Bracher, A.; Kozany, C.; Thost, A. K.; Hausch, F. Structuralcharacterization of the PPIase domain of FKBP51, a cochaperone ofhuman Hsp90. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2011, 67, 549−559.